CSF1 and systemic lupus erythematosus: These data highlight the potential value of M-CSF as biomarker in the clinical management of SLE patients (67), although it is not clear yet if in SLE patients with isolated atherosclerosis, the levels of M-CSF are a reliable biomarker of adverse outcomes in cardiovascular events.